LEXICON PHARMACEUTICALS INC
LXRXNASDAQTrading Snapshot
- Day Range
- $1.41 – $1.50
- 52-Week Range
- $1.10 – $2.68
- Volume (shares)
- 558,573
- Avg Volume (shares)
- —
- Shares Outstanding
- 445.0M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- $50M
- Last Q Revenue
- $692,000
- P/E Ratio
- —
- P/S Ratio
- 16.0x
- EPS (TTM)
- $-0.15
- Dividend Yield
- —
- Dilution (1yr)
- +0.5%
LEXICON PHARMACEUTICALS INC
LXRX
StockOtter · stockotter.spaceAbout LEXICON PHARMACEUTICALS INC
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 f
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet ac
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report)'s share price fell 5.2% during trading on Monday. The company traded as low as $1.72 and last traded at $1.7250. Approximately 1,402,888 shares changed hands
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1 safety data. Top-line resu
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential to win FDA approval for a new indication.